Australia Revives Debate Over Unique Suffixes For Biologic Medicines
Executive Summary
The Australian medicines agency has launched a public consultation on whether specific naming requirements should be applied to biologicals and their biosimilar versions. Among the options are the use of bar codes and suffixes to ensure individual products can be identified for traceability and pharmacovigilance purposes.